In Vitro and in silico strategies to identify OATP1B1 Inhibitors and Predict Clinical Drug-Drug Interactions

Pharmaceutical Research

Volumn 29, Issue 2, 2012, Pages 411-426

  Karlgren, Maria ^a   Ahlin, Gustav ^a   Bergström, Christel A S ^a   Svensson, Richard ^a   Palm, Johan ^b   Artursson, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

In silico; In vitro in vivo extrapolation; Inhibition; MRP2; OATP1B1

Indexed keywords

ADEFOVIR; AMPRENAVIR; ATAZANAVIR; ATORVASTATIN; BROMSULFOPHTHALEIN; CYCLOSPORIN A; DIETHYLSTILBESTROL; DIPYRIDAMOLE; ERYTHROMYCIN; ESTRADIOL 17 GLUCURONIDE; ESTRONE SULFATE; FENOFIBRATE; GEMFIBROZIL; GLIBENCLAMIDE; IVERMECTIN; LOPINAVIR; NICARDIPINE; OLMESARTAN; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN; PROGESTERONE; RIFAMYCIN; RITONAVIR; SALAZOSULFAPYRIDINE; SAQUINAVIR; SILYMARIN; TAUROCHOLIC ACID; TAUROLITHOCHOLIC ACID; UNINDEXED DRUG; VALSARTAN; DRUG DERIVATIVE; ESTRADIOL; ESTRADIOL 17 BETA GLUCURONIDE; ESTRADIOL-17 BETA-GLUCURONIDE; HEPTANOIC ACID DERIVATIVE; ORGANIC ANION TRANSPORTER; PYRROLE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN HEK293; COMPUTER MODEL; COMPUTER PREDICTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INTERACTION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL; TRANSPORT KINETICS; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG ANTAGONISM; GENE EXPRESSION; METABOLISM;

COMPUTER SIMULATION; DRUG INTERACTIONS; ESTRADIOL; GENE EXPRESSION; HEK293 CELLS; HEPTANOIC ACIDS; HUMANS; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; PYRROLES;

EID: 84859346272     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0564-9     Document Type: Article

References (51)

1. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 2007;35(8):1333-40. (Pubitemid 47121774)
2. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999;274(52):37161-8.
3. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36.
4. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001;276(13):9626-30.
5. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003;304(1):223-8. (Pubitemid 36008932)
6. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005;78(4):388-99. (Pubitemid 41393674)
7. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-81. (Pubitemid 44908269)
8. Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35(8):1400-7. (Pubitemid 47121782)
9. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet. 2004;19(3):171-9.
10. Yamaguchi H, Okada M, Akitaya S, Ohara H, Mikkaichi T, Ishikawa H, et al. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006;47(6):1196-202. (Pubitemid 43830711)
11. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, et al. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006;318(1):395-402.
12. Kindla J, Fromm MF, Konig J. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol. 2009;5(5):489-500.
13. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2008;36(4):663-9. (Pubitemid 351468371)
14. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76(2):167-77. (Pubitemid 39013406)
15. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther. 2007;81(3):414-9. (Pubitemid 46364484)
16. Kindla J, Muller F, Mieth M, Fromm MF, Konig J. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP)1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011;39(6):1047-53.
17. Poirier A, Funk C, Lave T, Noe J. New strategies to address drug-drug interactions involving OATPs. Curr Opin Drug Discov Dev. 2007;10(1):74-83. (Pubitemid 46438260)
18. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008;51(19):5932-42.
19. Matsson P, Englund G, Ahlin G, Bergstrom CA, Norinder U, Artursson P. A global drug inhibition pattern for the human ATPbinding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther. 2007;323(1):19-30. (Pubitemid 47443263)
20. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res. 2009;26(8):1816-31.
21. Pedersen JM, Matsson P, BergstromCA,Norinder U, Hoogstraate J, Artursson P. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem. 2008;51(11):3275-87. (Pubitemid 351821886)
22. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34(7):1229-36.
23. Dollery CT, editor. Therapeutic drugs. 2. ed. Edinburgh: Churchill Livingstone; 1999.
24. Goodman LS, Gilman A, Brunton LL, editors. Goodman & Gilman's the pharmacological basis of therapeutics [Electronic resource]. New York: McGraw-Hill; 2005.
25. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004;24(12):1732-47. (Pubitemid 39578961)
26. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 2001;1(4):382-6. (Pubitemid 33681704)
27. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47(5):570-8. (Pubitemid 351442013)
28. van der Lee MJ, Blenke AA, Rongen GA, Verwey-van Wissen CP, Koopmans PP, Pharo C, et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother. 2007;51(11):4098-104. (Pubitemid 350057810)
29. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther. 2006;316(1):336-48. (Pubitemid 41832613)
30. Vieth M, Siegel MG, Higgs RE, Watson IA, Robertson DH, Savin KA, et al. Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem. 2004;47(1):224-32. (Pubitemid 38040506)
31. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999;274(24):17159-63.
32. Fehrenbach T, Cui Y, Faulstich H, Keppler D. Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003;368(5):415-20. (Pubitemid 37491501)
33. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273(1):251-60. (Pubitemid 30426895)
34. Bachmakov I, Glaeser H, Fromm MF, Konig J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008;57(6):1463-9.
35. Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics. 2008;18(11):937-42.
36. Balaban AT. Topological indices based on topological distances in molecular graphs. Pure & Appl Chem. 1983;55(2):199-206.
37. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693-705.
38. Pham PA, la Porte CJ, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother. 2009;53(10):4385-92.
39. Kido Y, Matsson P, Giacomini KM. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem. 2011;54(13):4548-58.
40. Chang C, Pang KS, Swaan PW, Ekins S. Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther. 2005;314(2):533-41. (Pubitemid 41043833)
41. Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res. 2007;24(2):239-47. (Pubitemid 46072183)
42. Noe J, Portmann R, Brun ME, Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007;35(8):1308-14. (Pubitemid 47121771)
43. Busti AJ, Bain AM, Hall 2nd RG, Bedimo RG, Leff RD, Meek C, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008;51(6):605-10.
44. Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. Hepatic transport of bile salts. Semin Liver Dis. 2000;20(3):273-92.
45. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 2006;78(18):2131-45.
46. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78(2):154-67. (Pubitemid 41112284)
47. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130(6):1793-806.
48. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006;80(6):607-20. (Pubitemid 44920223)
49. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513-22. (Pubitemid 41017600)
50. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 2001;46(1-3):27-43.
51. Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003;25(2):459-71. (Pubitemid 36286913)